Healio

Oral octreotide efficacy maintained in more than 90% of adults with acromegaly at 3 years

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. As Healio previously reported, more than 90% of ...
Healio

Once-monthly octreotide provides sustained acromegaly control with fewer injections

Please provide your email address to receive an email when new articles are posted on . Once-monthly subcutaneous octreotide was associated with persistent control of IGF-I and growth hormone levels ...
ascopubs.org

A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) with disease-related ...

Placebo controlled, double blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): ...
Nasdaq

Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients

Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom ...
FierceBiotech

Chiasma Reports Successful Oral Delivery Of A Peptide In Clinical Study

On Track To Initiate Pivotal Trial Of Octreolin TM (An Oral Form Of Octreotide Acetate) In Patients With Acromegaly By Year End 2010 NEW YORK and JERUSALEM, June 14 /PRNewswire/ -- Chiasma, Inc., a ...
Nasdaq

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.

PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of the first and ...